What's Happening?
Invivoscribe, a leader in precision diagnostics, has announced the launch of the PrepQuant System, a new sample preparation platform designed to standardize and streamline pre-analytical workflows in molecular testing. This system integrates nucleic acid
extraction, concentration, and quantification into a single automated instrument, aiming to reduce costs and eliminate inconsistencies in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation, the PrepQuant System is assay agnostic and can handle various specimen types, including blood, plasma, and bone marrow. It is set to be unveiled at the American Association for Cancer Research Annual Meeting in San Diego, with commercial shipments in North America expected by August 2026.
Why It's Important?
The introduction of the PrepQuant System is significant for the field of precision medicine, where the reliability of test results is crucial. By reducing variability in sample preparation, the system ensures consistent, high-quality results, which is vital for accurate diagnostics and treatment planning. This advancement could lead to more efficient laboratory operations, lower costs, and improved patient outcomes. The system's ability to handle multiple specimen types and its integration of several processes into one platform represent a major step forward in molecular testing technology.
What's Next?
Invivoscribe plans to expand the PrepQuant System's capabilities with new kit releases by the end of 2026, enhancing its versatility across molecular testing. The company is also preparing for the system's European availability in January 2027. As the system becomes more widely adopted, it may prompt other companies to innovate similar solutions, potentially transforming the landscape of molecular diagnostics.
